Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections

Area of Science:

• Urology
• Infectious Diseases
• Immunology

Background:

• Recurrent urinary tract infections (UTIs) affect 5-10% of women, significantly impacting quality of life.
• MV140, a sublingual inactivated bacterial preparation, has demonstrated potential benefits in prior observational studies.
• A need exists for effective preventative strategies against recurrent UTIs.

Purpose of the Study:

• To evaluate the efficacy of MV140 in preventing recurrent UTIs in women.
• To compare the effectiveness of 3-month and 6-month MV140 treatment regimens against placebo.
• To assess the impact of MV140 on health-related quality of life.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial involving 240 women aged 18-75 with recurrent UTIs.
• Participants were assigned to receive either MV140 for 3 or 6 months, or a placebo for 6 months (1:1:1 ratio).
• The primary endpoint was the number of UTIs over a 9-month period post-3-month intervention; secondary endpoints included UTI-free rates and time to onset.

Main Results:

• MV140 significantly reduced UTI episodes compared to placebo, with median episodes of 0.0 vs 3.0 (P<0.001).
• UTI-free rates were higher in MV140 groups (56-58%) versus placebo (25%).
• Adverse effects were infrequent and not clinically limiting across all groups.

Conclusions:

• MV140 demonstrates promising clinical efficacy in reducing the incidence of recurrent UTIs in women.
• Both 3-month and 6-month MV140 treatment durations appear effective.
• MV140 represents a potentially valuable therapeutic option for managing recurrent UTIs.